JP2022513164A - 胎盤由来同種car-t細胞およびその使用 - Google Patents
胎盤由来同種car-t細胞およびその使用 Download PDFInfo
- Publication number
- JP2022513164A JP2022513164A JP2021531011A JP2021531011A JP2022513164A JP 2022513164 A JP2022513164 A JP 2022513164A JP 2021531011 A JP2021531011 A JP 2021531011A JP 2021531011 A JP2021531011 A JP 2021531011A JP 2022513164 A JP2022513164 A JP 2022513164A
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- cell
- cells
- car
- peripheral blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000735 allogeneic effect Effects 0.000 title claims description 28
- 210000002826 placenta Anatomy 0.000 title description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 227
- 210000004027 cell Anatomy 0.000 claims abstract description 199
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 129
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 92
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000003169 placental effect Effects 0.000 claims abstract description 27
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims abstract description 9
- 201000005787 hematologic cancer Diseases 0.000 claims abstract description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims abstract description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims description 19
- 238000010361 transduction Methods 0.000 claims description 19
- 230000026683 transduction Effects 0.000 claims description 19
- 108091008874 T cell receptors Proteins 0.000 claims description 16
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 13
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 12
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 12
- 208000024908 graft versus host disease Diseases 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 108091033409 CRISPR Proteins 0.000 claims description 10
- 238000010354 CRISPR gene editing Methods 0.000 claims description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 10
- 238000003209 gene knockout Methods 0.000 claims description 8
- 230000002147 killing effect Effects 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- 230000004077 genetic alteration Effects 0.000 claims description 7
- 231100000118 genetic alteration Toxicity 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 7
- 230000004580 weight loss Effects 0.000 claims description 7
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 6
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 5
- 102000001398 Granzyme Human genes 0.000 claims description 5
- 108060005986 Granzyme Proteins 0.000 claims description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 5
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 4
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 4
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 229930192851 perforin Natural products 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 3
- 102100033467 L-selectin Human genes 0.000 claims description 3
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 1
- 230000001976 improved effect Effects 0.000 abstract description 5
- 238000010586 diagram Methods 0.000 abstract 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 74
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 74
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000004068 intracellular signaling Effects 0.000 description 18
- 241001430294 unidentified retrovirus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 241000713666 Lentivirus Species 0.000 description 15
- 239000012636 effector Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 14
- 230000009257 reactivity Effects 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000012642 immune effector Substances 0.000 description 11
- 229940121354 immunomodulator Drugs 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 241000283984 Rodentia Species 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 241001272567 Hominoidea Species 0.000 description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- -1 CD11c Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 102100024263 CD160 antigen Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102100029197 SLAM family member 6 Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000013349 risk mitigation Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
【選択図】なし
Description
出発物質胎盤血(Placenta Blood)(ヒト臍帯血(UCB)および/またはヒト胎盤灌流液(HPP)の両方を含む)を、LifebankUSAを通じてインフォームドコンセントを得て採集する。採集後、出発物質を、ヘタスターチRBC沈降またはFicoll-Paque密度勾配細胞分離を使用して単核細胞(MNC)について濃縮させる。次いで、MNCに、CD25+T制御性T細胞(Treg)を枯渇させるために陽性選択のプロセスを受けさせ、続いて、Militenyiビーズ細胞分離キットを使用してCD4+およびCD8+T細胞について陽性選択を受けさせる。単離されたT細胞のアリコートを、細胞が凍結される前に、血清学および滅菌試験ならびに表現型分析のために採集する。
非改変P-T細胞:
単離されたP-T細胞を解凍し、CD4+CD25+CD127-Tregの除去のためにMiltenyi抗CD25ビーズを使用してCD25枯渇を受けさせ(T細胞単離工程の前に含めることができる)、Invitrogenからの抗CD3/抗CD28ダイナビーズ(Dynabeads)(1:1のビーズ:細胞比)を使用して、またはMiltenyiからの抗CD3/抗CD28ナノ粒子トランザクト(Transact)(1:100の容量希釈)を使用して活性化する。次いで、100IU/mLのIL-2、10ng/mLのIL-7+10ng/mLのIL-15、または100IU/mLのIL-2+10ng/mLのIL-7を使用して細胞を増殖させる。追加の再刺激を12~14日目に完了し、細胞をGrex容器内で最長21日まで増殖させ、増殖倍率を最大化させる。
単離されたT細胞(凍結前にCD25枯渇を受けた)を解凍し、Miltenyiからの抗CD3/抗CD28ナノ粒子トランザクト(1:100の容量希釈)を使用して活性化した。次いで、細胞を、100IU/mLのIL-2を使用して、Grex容器中で増殖させた。3日目に、ウイルス前スピン法を使用して、レトロネクチンでコーティングしたプレート上でCD19 CARレンチウイルス(LV)またはレトロウイルス(RV)のいずれかで細胞を形質導入した。次いで、培地供給を2~3日ごとに行いながら、細胞を15日目まで培養した。
癌細胞株に対する15日目のP-CD19 CAR-T細胞の細胞溶解活性
活性化UCB-T細胞を、スパイノキュレーション(spinoculation)を使用して、UCB-T培養の2~4日目にCD19 CARレトロウイルスまたはレンチウイルスで形質導入した。CARベクターがMycタグを含有する場合、FITC標識組換えCD19-Fc融合タンパク質または抗Myc PE抗体のいずれかを使用して、CAR発現を検出した。UCB-CAR-T活性を、以下の2つのアッセイを使用して評価した。
インビボでは、P-CD19 CAR-T細胞の抗腫瘍活性を、NSGマウスにおける播種性リンパ腫異種移植片モデルを使用して評価した。Daudi細胞(3×106)を発現するルシフェラーゼを、0日目に静脈内(IV)注射し、続いてP-CD19 CAR-T細胞をIV注射した。表1に概説したCD8+CD19 CAR+頻度に従ってP-T細胞を投与した(P-T:RV:7日目に14×106の1回投与、LV:7日目に20×106の1回投与、または7日目、10日目、および14日目に20×106の3回投与)。生物発光イメージング(BLI)および生存率を主要評価項目として使用した。
TRACは、ガイドRNA(gRNA)を使用して、TRAC遺伝子座の第1のエクソンに対して標的化した。Cas9およびgRNAの化学的に改質したRNA形態を、ヌクレオフェクション(Nucleofection)(Lonza)を介してP-T培養の6~8日目にP-T細胞にトランスフェクトした。遺伝子改変効率を、TCRα/βまたはCD3に対する抗体を使用したフローサイトメトリーによって監視した。
2つの独立したアッセイを使用して、P-T細胞に対するPMBC、またはPBMCに対するP-T細胞の同種反応性を測定した。最初のアッセイでは、同種反応性を、4時間の共培養において、1人のドナーから別のドナーに対する細胞の殺傷活性として測定した。標的細胞をPKH26で標識し、細胞傷害性を全標的細胞に対する死滅標的細胞の割合として表した。2番目のアッセイでは、同種反応性を、別のドナーと共培養したときの1人のドナーのT細胞の優先的増殖として測定した。2人のドナー由来の細胞を異なる染料(CFSEおよびPKH26)で標識し、1:1の比で4日間共培養する。染料の希釈は、細胞増殖を示し、高強度を有する細胞の割合の減少または平均蛍光強度の変化として表すことができる。
GvHDのNCGマウスモデルにおいて、非改変の21日間増殖させたP-T細胞の同種反応性(異種同種反応性)を試験した。このモデルでは、PBMCは体重減少として測定可能なGvHDを引き起こす。3人のドナーおよび対照PMBC由来の3,000万個のCD25枯渇P-T細胞を、IV経路を介してNCGマウスに注入した。動物の体重を経時的に監視した。
Claims (42)
- キメラ抗原受容体(CAR)を発現するT細胞集団であって、前記T細胞が胎盤T細胞である、T細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞、胎盤灌流液T細胞、またはこれらの混合物である、請求項1に記載のT細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞である、請求項1に記載のT細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞と胎盤灌流液T細胞との混合物である、請求項1に記載のT細胞集団。
- 前記CARが、トランスフェクションによって前記細胞に導入されている、請求項1~4のいずれか一項に記載のT細胞集団。
- 前記CARが、ウイルス形質導入によって前記細胞に導入されている、請求項1~4のいずれか一項に記載のT細胞集団。
- 前記CARが、レトロウイルスベクターを用いたウイルス形質導入によって前記細胞に導入されている、請求項6に記載のT細胞集団。
- 前記CARが、レンチウイルスベクターを用いたウイルス形質導入によって前記細胞に導入されている、請求項6に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のCD45RAを発現する細胞を有する、請求項1~8のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のCD27を発現する細胞を有する、請求項1~9のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のCCR7を発現する細胞を有する、請求項1~10のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のCD127を発現する細胞を有する、請求項1~11のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも低い割合のCD57を発現する細胞を有する、請求項1~12のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のCD62Lを発現する細胞を有する、請求項1~13のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも低い割合のCD25を発現する細胞を有する、請求項1~14のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも高い割合のLag-3+を発現する細胞を有する、請求項1~15のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも低い割合のTim-3を発現する細胞を有する、請求項1~16のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株の高いインビトロ殺傷を呈する、請求項1~17のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株に対するインビトロチャレンジにおいて、より多くの量のパーフォリンを発現する、請求項1~18のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株に対するインビトロチャレンジにおいて、より多くの量のGM-CSFを発現する、請求項1~19のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株に対するインビトロチャレンジにおいて、より多くの量のTNF-aを発現する、請求項1~20のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株に対するインビトロチャレンジにおいて、より多くの量のIL-2を発現する、請求項1~21のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、癌細胞株に対するインビトロチャレンジにおいて、より多くの量のグランザイムBを発現する、請求項1~22のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、インビボ癌モデルにおいて生存率の増加をもたらす、請求項1~23のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、インビボ癌モデルにおいて体重減少の低下をもたらす、請求項1~24のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核細胞T細胞集団よりも、インビボ癌モデルにおいて移植片対宿主病(GvHD)の減少をもたらす、請求項1~25のいずれか一項に記載のT細胞集団。
- 前記末梢血単核細胞T細胞集団が、前記CARも発現する、請求項9~26のいずれか一項に記載のT細胞集団。
- 前記CARが、トランスフェクションによって前記末梢血単核細胞T細胞集団に導入されている、請求項27に記載のT細胞集団。
- 前記CARが、ウイルス形質導入によって前記末梢血単核細胞T細胞集団に導入されている、請求項27に記載のT細胞集団。
- 前記CARが、レトロウイルスベクターを用いたウイルス形質導入によって、前記末梢血単核細胞T細胞集団に導入されている、請求項29に記載のT細胞集団。
- 前記CARが、レンチウイルスベクターを用いたウイルス形質導入によって、前記末梢血単核細胞T細胞集団に導入されている、請求項29に記載のT細胞集団。
- 前記末梢血単核細胞T細胞集団に導入されている前記CARが、前記T細胞集団によって発現される同一のCARである、請求項1~31のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、宿主に対する免疫原性を低減するためのさらなる遺伝子変化を含む、請求項1~32のいずれか一項に記載のT細胞集団。
- 前記遺伝子変化が、遺伝子ノックアウトである、請求項33に記載のT細胞集団。
- 前記遺伝子ノックアウトが、T細胞受容体(TCR)ノックアウトである、請求項34に記載のT細胞集団。
- 前記遺伝子ノックアウトが、T細胞受容体アルファ定常遺伝子(TRAC)ノックアウトである、請求項34に記載のT細胞集団。
- 前記さらなる遺伝子変化が、トランスフェクション、レトロウイルス形質導入、またはレンチウイルス形質導入によって達成される、請求項33~36のいずれか一項に記載のT細胞集団。
- 前記さらなる遺伝子変化が、CRISPR、ターレン、またはジンクフィンガー技術の使用によって達成される、請求項33~36のいずれか一項に記載のT細胞集団。
- 癌またはその症状の治療を、それを必要とする患者において行う方法であって、前記方法が、前記患者において前記癌またはその症状を緩和するのに有効な量の請求項1~38のいずれか一項に記載のT細胞集団を前記患者に投与する工程を含む、方法。
- 前記癌が血液癌である、請求項39に記載の方法。
- 前記血液癌が、B細胞癌である、請求項40に記載の方法。
- 前記T細胞集団が、前記患者に対して同種である、請求項39~41のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774142P | 2018-11-30 | 2018-11-30 | |
US62/774,142 | 2018-11-30 | ||
US201962878736P | 2019-07-25 | 2019-07-25 | |
US62/878,736 | 2019-07-25 | ||
PCT/US2019/064074 WO2020113234A1 (en) | 2018-11-30 | 2019-12-02 | Placenta-derived allogeneic car-t cells and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513164A true JP2022513164A (ja) | 2022-02-07 |
JPWO2020113234A5 JPWO2020113234A5 (ja) | 2022-12-19 |
Family
ID=69005946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021531011A Pending JP2022513164A (ja) | 2018-11-30 | 2019-12-02 | 胎盤由来同種car-t細胞およびその使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220118014A1 (ja) |
EP (1) | EP3886876A1 (ja) |
JP (1) | JP2022513164A (ja) |
KR (1) | KR20210111244A (ja) |
CN (1) | CN113395972A (ja) |
AU (1) | AU2019387571A1 (ja) |
BR (1) | BR112021010132A2 (ja) |
CA (1) | CA3120364A1 (ja) |
MX (1) | MX2021006402A (ja) |
PH (1) | PH12021551246A1 (ja) |
SG (1) | SG11202105217RA (ja) |
WO (1) | WO2020113234A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL293462A (en) * | 2019-12-04 | 2022-07-01 | Celularity Inc | Allogeneic car-t cells derived from the placenta and their uses |
AU2021309145A1 (en) * | 2020-07-16 | 2023-02-16 | Legend Biotech Ireland Limited | CD19 binding molecules and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536824A (ja) * | 2006-05-11 | 2009-10-22 | 直子 武部 | 臍帯血幹細胞の回収方法及び使用方法 |
US20160237407A1 (en) * | 2015-02-17 | 2016-08-18 | Batu Biologics, Inc. | Universal donor chimeric antigen receptor cells |
JP2016537362A (ja) * | 2013-11-15 | 2016-12-01 | アントフロゲネシス コーポレーション | ヒト胎盤灌流液細胞、その亜集団を含む組成物、およびそれらの使用 |
WO2017015427A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
JP2018502114A (ja) * | 2014-12-31 | 2018-01-25 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
WO2018115887A1 (en) * | 2016-12-21 | 2018-06-28 | Ucl Business Plc | Therapeutic cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
KR102452767B1 (ko) * | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (car) t-세포의 인간 적용 |
CN106536558A (zh) * | 2014-04-10 | 2017-03-22 | 西雅图儿童医院(Dba西雅图儿童研究所) | 转基因遗传标签和使用的方法 |
AU2015317316A1 (en) * | 2014-09-19 | 2017-04-06 | City Of Hope | Central memory T cells for adoptive T cell therapy |
EP3025719B1 (en) * | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
HRP20211648T1 (hr) * | 2014-12-12 | 2022-02-04 | 2Seventy Bio, Inc. | Kimerni receptori antigena bcma |
US20160228547A1 (en) * | 2015-02-06 | 2016-08-11 | Batu Biologics, Inc. | Chimeric antigen receptor targeting of tumor endothelium |
EP4234685A3 (en) * | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
JP2018520209A (ja) * | 2015-05-26 | 2018-07-26 | セルラリティ インコーポレイテッド | 刺激胎盤幹細胞を使用した血管新生 |
CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
WO2017100428A1 (en) * | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
-
2019
- 2019-12-02 JP JP2021531011A patent/JP2022513164A/ja active Pending
- 2019-12-02 BR BR112021010132-2A patent/BR112021010132A2/pt unknown
- 2019-12-02 EP EP19828010.9A patent/EP3886876A1/en active Pending
- 2019-12-02 CA CA3120364A patent/CA3120364A1/en active Pending
- 2019-12-02 CN CN201980078364.2A patent/CN113395972A/zh active Pending
- 2019-12-02 US US17/309,451 patent/US20220118014A1/en active Pending
- 2019-12-02 SG SG11202105217RA patent/SG11202105217RA/en unknown
- 2019-12-02 MX MX2021006402A patent/MX2021006402A/es unknown
- 2019-12-02 KR KR1020217016359A patent/KR20210111244A/ko unknown
- 2019-12-02 WO PCT/US2019/064074 patent/WO2020113234A1/en unknown
- 2019-12-02 AU AU2019387571A patent/AU2019387571A1/en active Pending
-
2021
- 2021-05-28 PH PH12021551246A patent/PH12021551246A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536824A (ja) * | 2006-05-11 | 2009-10-22 | 直子 武部 | 臍帯血幹細胞の回収方法及び使用方法 |
JP2016537362A (ja) * | 2013-11-15 | 2016-12-01 | アントフロゲネシス コーポレーション | ヒト胎盤灌流液細胞、その亜集団を含む組成物、およびそれらの使用 |
JP2018502114A (ja) * | 2014-12-31 | 2018-01-25 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
US20160237407A1 (en) * | 2015-02-17 | 2016-08-18 | Batu Biologics, Inc. | Universal donor chimeric antigen receptor cells |
WO2017015427A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2018115887A1 (en) * | 2016-12-21 | 2018-06-28 | Ucl Business Plc | Therapeutic cells |
Non-Patent Citations (1)
Title |
---|
SHERIDAN, CORMAC, NATURE BIOTECHNOLOGY, vol. 36, no. 5, JPN6023044487, May 2018 (2018-05-01), pages 375 - 377, ISSN: 0005186394 * |
Also Published As
Publication number | Publication date |
---|---|
CN113395972A (zh) | 2021-09-14 |
US20220118014A1 (en) | 2022-04-21 |
AU2019387571A1 (en) | 2021-06-03 |
SG11202105217RA (en) | 2021-06-29 |
CA3120364A1 (en) | 2020-06-04 |
BR112021010132A2 (pt) | 2021-08-24 |
KR20210111244A (ko) | 2021-09-10 |
MX2021006402A (es) | 2021-08-11 |
EP3886876A1 (en) | 2021-10-06 |
WO2020113234A1 (en) | 2020-06-04 |
PH12021551246A1 (en) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220025001A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
KR20200071079A (ko) | 공동-자극을 위한 신규한 플랫폼, 신규한 car 설계 및 입양 세포 치료를 위한 다른 향상 | |
KR20200069358A (ko) | 키메라 항원 수용체 발현 세포의 제조 방법 | |
KR20200120939A (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
KR20170093254A (ko) | 키메라 항원 수용체-발현 세포를 제조하는 방법 | |
EP3568416A1 (en) | Chimeric antigen receptors targeting tim-1 | |
CN115052902B (zh) | 淋巴细胞-抗原提呈细胞共刺激因子及其应用 | |
JP2022514023A (ja) | 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用 | |
JP2021534802A (ja) | 複数のhla−gアイソフォームに対するキメラ抗原レセプター | |
US20220064255A1 (en) | Anti-tcr antibody molecules and uses thereof | |
KR20230084470A (ko) | 면역 세포 기능의 향상 | |
US20230048244A1 (en) | Anti-tcr antibody molecules and uses thereof | |
CN110819596B (zh) | 具有增强的迁移能力的修饰的细胞 | |
JP2022513164A (ja) | 胎盤由来同種car-t細胞およびその使用 | |
US20230108300A1 (en) | Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease | |
KR20220004076A (ko) | 리툭시맙-내성 키메라 항원 수용체 및 이의 용도 | |
KR20220110199A (ko) | 태반-유래 동종이계 car-t 세포 및 이의 용도 | |
RU2816370C2 (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240129 |